Liqiong Ding, Ping Jiang, Xinfeng Xu, Wanzhen Lu, Chan Yang, Lin Li, Pingzheng Zhou, Shuwen Liu
European journal of pharmacology 2021 Feb 05Herpes simplex virus type 2 (HSV-2) is a highly contagious sexually transmitted virus. The increasing emergence of drug-resistant viral strains has highlighted the crucial need for the development of new anti-HSV-2 drugs with different mechanisms. Ion channels that govern a wide range of cellular functions represent attractive targets for viral manipulation. Here, we tried to identify novel compounds to suppress HSV-2 infection in vitro by screening a small library with ion channels modulators. We found that several T-type calcium channel blockers including benidipine, lercanidipine, lomerizine and mibefradil inhibited HSV-2 infection, while L-type calcium channel blockers nifedipine and nitrendipine showed no significant effect on HSV-2 infection. Furthermore, we found that benidipine exerted the antiviral effect by suppressing the expression of viral genes in the late stage of viral infection. In conclusion, our study suggested that T-type calcium channel blockers, which are clinically wide used, could effectively inhibit HSV-2 infection. These findings could shed light on the mechanism and pharmacological study for HSV-2 infection in the future. Copyright © 2020 Elsevier B.V. All rights reserved.
Liqiong Ding, Ping Jiang, Xinfeng Xu, Wanzhen Lu, Chan Yang, Lin Li, Pingzheng Zhou, Shuwen Liu. T-type calcium channels blockers inhibit HSV-2 infection at the late stage of genome replication. European journal of pharmacology. 2021 Feb 05;892:173782
PMID: 33279521
View Full Text